Risk-adapted treatment in clinical stage I testicular seminoma: the third Spanish Germ Cell Cancer Group study

Jorge Aparicio, Pablo Maroto, Xavier García del Muro, Josep Gumà, Alfonso Sánchez-Muñoz, Mireia Margelí, Montserrat Doménech, Romá Bastús, Antonio Fernández, Marta López-Brea, Josefa Terrassa, Andrés Meana, Purificación Martínez del Prado, Javier Sastre, Juan J Satrústegui, Regina Gironés, Lidia Robert, José R Germà

Producció científica: Contribució a una revistaArticleRecercaAvaluat per experts

96 Cites (Scopus)

Resum

PURPOSE: To confirm the efficacy of a risk-adapted treatment approach for patients with clinical stage I seminoma. The aim was to reduce both the risk of relapse and the proportion of patients receiving adjuvant chemotherapy while maintaining a high cure rate.

PATIENTS AND METHODS: From 2004 to 2008, 227 patients were included after orchiectomy in a multicenter study. Eighty-four patients (37%) presented no local risk factors, 44 patients (19%) had tumors larger than 4 cm, 25 patients (11%) had rete testis involvement, and 74 patients (33%) had both criteria. Only the latter group received two courses of adjuvant carboplatin, whereas the rest were managed by surveillance.

RESULTS: After a median follow-up time of 34 months, 16 relapses (7%) have been documented (15 [9.8%] among patients on surveillance and one [1.4%] among those treated with carboplatin). All relapses occurred in retroperitoneal lymph nodes, except for one case in pelvic nodes. Median node size was 25 mm, and median time to recurrence was 14 months. All patients were rendered disease-free with chemotherapy. The actuarial 3-year disease-free survival rate was 88.1% (95% CI, 82.3% to 93.9%) for patients on surveillance and 98.0% (95% CI, 94.0% to 100%) for those treated with adjuvant chemotherapy. Overall 3-year survival was 100%.

CONCLUSION: With the limitations of the short follow-up duration, we confirm that a risk-adapted approach is effective for stage I seminoma. Adjuvant carboplatin seems adequate treatment for patients with 2 risk criteria, as is active surveillance for those with 0 to one risk factors. More reliable predictive factors are needed to improve the applicability of this model.

Idioma originalEnglish
Pàgines (de-a)4677-81
Nombre de pàgines5
RevistaJournal of Clinical Oncology
Volum29
Número35
DOIs
Estat de la publicacióPublicada - 10 de des. 2011

Fingerprint

Navegar pels temes de recerca de 'Risk-adapted treatment in clinical stage I testicular seminoma: the third Spanish Germ Cell Cancer Group study'. Junts formen un fingerprint únic.

Com citar-ho